Abstract 264: Circulating Tnni3k Levels Are Useful Diagnosis Biomarker for Acute Ischemic Myocardial Diseases

Abstract

Our recent data showed that TNNI3K, a MAP kinase specifically expressed in cardiac muscles and interacted with cardiac troponin I, TNNI3K high-expression enhanced cardiac performance, attenuated ischemia-induced ventricular remodeling in mice with myocardial infarction, and protected the myocardium from ischemic injury.

In the present study, availability of circulating TNNI3K level was investigated using anti-TNNI3K polyclonal antibodies with ELISA, in patients diagnosed as AMI, chronic heart failure and acute renal failure; and in healthy volunteers groups. Data shown that circulating TNNI3K levels were significantly higher in AMI when compared with other two groups (p<0.001), indicating that measurement of circulating TNNI3K is a novel and useful diagnosing tool for AMI. Then, we made an anti-TNNI3K monoclonal antibody to investigate whether circulating TNNI3K levels play the same role for diagnosis of ischemic myocardial diseases, the availability of serum TNNI3K level was investigated with anti-TNNI3K monoclonal-antibodies in AMI, chronic heart failure and acute renal failure patients, and in healthy volunteers respectively. Data shown that circulating TNNI3K levels were significantly higher in AMI (p<0.001) and sensitivity and specificity are higher, ROC curve is more best than that of polyclonal antibodies, indicating that measurement of circulating TNNI3K level using the monoclonal-antibodies may be a novel and useful tool to diagnose AMI. Furthermore, both ELISA and gold colloid methods are used to observe their sensitivity and specificity. Results showed that the sensitivity and specificity of anti-TNNI3K monoclonal antibody were higher than other biomarkers anti-TNNI3K monoclonal antibody and the measurment time in the gold colloid method is significantly shortened when compared with using ELISA method. In conclusion, using TNNI3K as a molecular target is a new potential approach for developing therapeutic or diagnostic agents for ischemic cardiac diseases by means of molecular biological techniques.